Breast cancer in the era of precision medicine

被引:71
作者
Sarhangi, Negar [1 ]
Hajjari, Shahrzad [2 ]
Heydari, Seyede Fatemeh [2 ]
Ganjizadeh, Maryam [2 ]
Rouhollah, Fatemeh [2 ]
Hasanzad, Mandana [1 ,2 ]
机构
[1] Univ Tehran Med Sci, Personalized Med Res Ctr, Endocrinol & Metab Clin Sci Inst, Tehran, Iran
[2] Islamic Azad Univ, Tehran Med Sci, Med Genom Res Ctr, Tehran, Iran
关键词
Breast cancer; Targeted treatment; Molecular profiling; Molecular subtype; Precision Medicine; LAPATINIB PLUS CAPECITABINE; GENETIC SUSCEPTIBILITY; ADJUVANT CHEMOTHERAPY; OVARIAN-CARCINOMA; OPEN-LABEL; PHASE-I; MUTATIONS; PARP; BRCA1; HETEROGENEITY;
D O I
10.1007/s11033-022-07571-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Breast cancer is a heterogeneous disorder with different molecular subtypes and biological characteristics for which there are diverse therapeutic approaches and clinical outcomes specific to any molecular subtype. It is a global health concern due to a lack of efficient therapy regimens that might be used for all disease subtypes. Therefore, treatment customization for each patient depending on molecular characteristics should be considered. Precision medicine for breast cancer is an approach to diagnosis, treatment, and prevention of the disease that takes into consideration the patient's genetic makeup. Precision medicine provides the promise of highly individualized treatment, in which each individual breast cancer patient receives the most appropriate diagnostics and targeted therapies based on the genetic profile of cancer. The knowledge about the molecular features and development of breast cancer treatment approaches has increased, which led to the development of new targeted therapeutics. Tumor genomic profiling is the standard of care for breast cancer that could contribute to taking steps to better management of malignancies. It holds great promise for accurate prognostication, prediction of response to common systemic therapies, and individualized monitoring of the disease. The emergence of targeted treatment has significantly enhanced the survival of patients with breast cancer and contributed to reducing the economic costs of the health system. In this review, we summarized the therapeutic approaches associated with the molecular classification of breast cancer to help the best treatment selection specific to the target patient.
引用
收藏
页码:10023 / 10037
页数:15
相关论文
共 102 条
[1]   ATM and breast cancer susceptibility [J].
Ahmed, M. ;
Rahman, N. .
ONCOGENE, 2006, 25 (43) :5906-5911
[2]   Expression of STK11 gene and its promoter activity in MCF control and cancer cells [J].
Alkaf, Asma ;
Al-Jafari, Abdulaziz ;
Wani, Tanveer A. ;
Alqattan, Somaya ;
Zargar, Seema .
3 BIOTECH, 2017, 7
[3]   Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update [J].
Amstutz, Ursula ;
Henricks, Linda M. ;
Offer, Steven M. ;
Barbarino, Julia ;
Schellens, Jan H. M. ;
Swen, Jesse J. ;
Klein, Teri E. ;
McLeod, Howard L. ;
Caudle, Kelly E. ;
Diasio, Robert B. ;
Schwab, Matthias .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (02) :210-216
[4]  
Anders C, 2008, ONCOLOGY-NY, V22, P1233
[5]   Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].
Andre, Fabrice ;
Ciruelos, Eva ;
Rubovszky, Gabor ;
Campone, Mario ;
Loibl, Sibylle ;
Rugo, Hope S. ;
Iwata, Hiroji ;
Conte, Pierfranco ;
Mayer, Ingrid A. ;
Kaufman, Bella ;
Yamashita, Toshinari ;
Lu, Yen-Shen ;
Inoue, Kenichi ;
Takahashi, Masato ;
Papai, Zsuzsanna ;
Longin, Anne-Sophie ;
Mills, David ;
Wilke, Celine ;
Hirawat, Samit ;
Juric, Dejan .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940
[6]   Hereditary Breast Cancer: The Era of New Susceptibility Genes [J].
Apostolou, Paraskevi ;
Fostira, Florentia .
BIOMED RESEARCH INTERNATIONAL, 2013, 2013
[7]   Treatment of HER2-positive breast cancer: current status and future perspectives [J].
Arteaga, Carlos L. ;
Sliwkowski, Mark X. ;
Osborne, C. Kent ;
Perez, Edith A. ;
Puglisi, Fabio ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (01) :16-32
[8]   Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy [J].
Ayoub, J. P. M. ;
Verma, Sh ;
Verma, Su .
CURRENT ONCOLOGY, 2012, 19 (02) :91-105
[9]  
Biancolella M, 2020, SEMIN CANCER BIOL
[10]   Genetics and Genomics of Breast Cancer: update and translational perspectives [J].
Biancolella, Michela ;
Testa, Barbara ;
Salehi, Leila Baghernajad ;
D'Apice, Maria Rosaria ;
Novelli, Giuseppe .
SEMINARS IN CANCER BIOLOGY, 2021, 72 :27-35